Company Overview and News

29
Chesapeake Stock Could Be a Good Pick for Some Investors

1h investorplace
Chesapeake Energy (NYSE:CHK) has been on a roller coaster ride for the past 12 months. The ups and downs of CHK stock price have been driven by fluctuations in fuel prices as well as the company’s struggle to pay down its massive debt load.
CHKDJ CKRGZ CHKDP CHK CHKVP CHK.WI CHKDH CHKVZ CHKDG CHKWZ

29
Chesapeake Energy stock slips to endanger 5-day win streak after analyst downgrade

2h marketwatch
Chesapeake Energy Corp. CHK, -0.11% was downgraded by SunTrust RH analyst Neal Dingmann, who said the oil and gas producer's turnaround could take longer than expected. The stock slipped 0.3% morning trade, after soaring 17% amid a five-session win streak through Monday. Dingmann cut his rating to hold, after being at buy for at least the past three years, and lowered his price target to $5 from $6.
CHKDJ CKRGZ CHKDP CHK CHKVP CHK.WI CHKDH CHKVZ CHKDG CHKWZ

173
The Zacks Analyst Blog Highlights: Cabot Oil, Chesapeake, Comstock, Southwestern and SilverBow

3h zacks
Chicago, IL –September 25, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Cabot Oil & Gas Corp. (COG - Free Report) , Chesapeake Energy Corp. (CHK - Free Report) , Comstock Resources, Inc. (CRK - Free Report) , Southwestern Energy Co.
CKRGZ CQP LNG CHKVP RAD CRK COG SBOW CHKDH CHKVZ CHKDG CHKWZ CHKDJ CHKDP CHK CHK.WI TITN

69
Top Analyst Upgrades and Downgrades: Barrick Gold, Blackstone, Chesapeake Energy, Dollar Tree, Intel, Qualcomm, Sirius XM, TI, Vale and More

3h 247wallst
Stocks have hit all-time highs, and Monday’s losses were followed with what looked to be a positive open on Tuesday for the major equity indexes. The markets are dealing with trade tariffs and with the Federal Reserve meeting this week. Many investors also have seen lower upside from buying on market pullbacks than in prior years. Now the investing community has to consider how to position their investments for the rest of 2018 and as 2019 approaches.
CHKVP AVP CHKDH CHKVZ CENT CLH ABT CNI CHKDG DLTR SIRI CHKDJ HUN CHKDP MS INTC ABX ABT CKRGZ ABX BX MCHP ON CADE CHKWZ NITE WEN HP BJ CZR CHK CHK.WI TRI QCOM TS CLX

29
CHK / Chesapeake Energy Corp. 424B5 (Prospectus)

5h sec.gov
424b5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-219649 The information contained in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement is not an offer to sell, and it is not a solicitation of a
CHK

29
CHK / Chesapeake Energy Corp. 424B5 (Prospectus)

5h sec.gov
424b5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-219649 The information contained in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement is not an offer to sell, and it is not a solicitation of a
CHK

29
CHK / Chesapeake Energy Corp. 424B5 (Prospectus)

5h sec.gov
424b5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-219649 The information contained in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement is not an offer to sell, and it is not a solicitation of a
CHK

29
CHK / Chesapeake Energy Corp. 424B5 (Prospectus)

5h sec.gov
424b5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-219649 The information contained in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement is not an offer to sell, and it is not a solicitation of a
CHK

29
CHK / Chesapeake Energy Corp. 424B5 (Prospectus)

5h sec.gov
424b5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-219649 The information contained in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement is not an offer to sell, and it is not a solicitation of a
CHK

29
CHK / Chesapeake Energy Corp. 424B5 (Prospectus)

5h sec.gov
424b5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-219649 The information contained in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement is not an offer to sell, and it is not a solicitation of a
CHK

29
CHK / Chesapeake Energy Corp. 424B5 (Prospectus)

5h sec.gov
424b5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-219649 The information contained in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement is not an offer to sell, and it is not a solicitation of a
CHK

29
CHK / Chesapeake Energy Corp. 424B5 (Prospectus)

5h sec.gov
424b5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-219649 The information contained in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement is not an offer to sell, and it is not a solicitation of a
CHK

29
CHK / Chesapeake Energy Corp. 424B5 (Prospectus)

5h sec.gov
424b5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-219649 The information contained in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement is not an offer to sell, and it is not a solicitation of a
CHK

29
CHK / Chesapeake Energy Corp. 424B5 (Prospectus)

5h sec.gov
424b5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-219649 The information contained in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement is not an offer to sell, and it is not a solicitation of a
CHK

29
CHK / Chesapeake Energy Corp. 424B5 (Prospectus)

5h sec.gov
424b5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-219649 The information contained in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement is not an offer to sell, and it is not a solicitation of a
CHK

CHK : Chesapeake Energy Corporation Stock Analysis and Research Report

2017-10-30 - Asif

The company own interests in approximately 22,700 oil and natural gas wells and produced an average of approximately 575 mboe per day in the 2016 fourth quarter, net to its interest. Chesapeake Energy has a large and geographically diverse resource base of onshore U.S. unconventional natural gas and liquids assets. Chesapeake Energy has leading positions in the liquids-rich resource plays of the Eagle Ford Shale in South Texas, the Utica Shale in Ohio, the Anadarko Basin in northwestern Oklahoma and the stacked pay in the Powder River Basin in Wyoming. Its natural gas resource plays are the Haynesville/Bossier Shales in northwestern Louisiana and East Texas and the Marcellus Shale in the northern Appalachian Basin in Pennsylvania. The company also own an oil and natural gas marketing business. The Company's estimated proved reserves as of December 31, 2016, were 1.708 bboe, an increase of 204 mmboe or 14%, from 1.504 bboe as of December 31, 2015. The increase in estimated proved res...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to CHK / Chesapeake Energy Corp. on message board site Silicon Investor.

Check Point Software (CHKP) Check Point Software (CHKP) Check Point Software (CHKP) Chesapeake Energy CHK Chesapeake Energy CHK Chesapeake Energy CHK
CHKR--insider expects it to double during next year CHKR--insider expects it to double during next year CHKR--insider expects it to double during next year Linda Bradford Raschke Linda Bradford Raschke Linda Bradford Raschke
Linda Bradford Raschke Linda Bradford Raschke Linda Bradford Raschke Schick Technologies (SCHK) Schick Technologies (SCHK) Schick Technologies (SCHK)
CHKE-Cherokee CHKE-Cherokee CHKE-Cherokee Churchill Resources Ltd. Churchill Resources Ltd. Churchill Resources Ltd.
CUSIP: 165167107